Gastroenterologie
a hepatologie

Komentář k doporučení Americké gastroenterologické asociace (AGA) pro léčbu středně těžké a těžké Crohnovy nemoci

Milan Lukáš¹

+ Affiliation
¹ Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. FeuersteinJD, HO EY, Shmidt E et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroentreology 2021; 160(7): 2496–2508. doi: 10.1053/j.gastro.2021.04.022.
2. Singh S, Proctor D, Scott FI et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroentreology 2021; 160(7): 2512–2556. doi: 10.1053/j.gastro.2021.04.023.
3. Ho EY, Singh S, Terdiman JP. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroentreology 2021; 160(7): 2557–2562. doi: 10.1053/j.gastro.2021.04.024.
4. Terdiman JP, Gruss CB, Heidelbaugh JJ et al. AGA Insitute Clinical Practice and Quality Management Committee. American Gastroentreogical Association Institure guidelines on the of thiopurines, methotrexate, and anti TNF bio­logic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013; 145(6): 1459–1463. doi: 10.1053/j.gastro.2013.10.047.
5. Torres J, Bonovas S, Doherty G et al. ECCO guidelines on therapeutics in Crohn’ s disease: medical treatment. J Crohn’s Colitis 2020; 14(1): 4–22. doi: 10.1093/ecco-jcc/jjz180.